AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors

BACKGROUND: Ociperlimab, a novel, humanized monoclonal antibody (mAb), binds to T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) with high affinity and specificity. Tislelizumab is an anti-programmed cell death protein 1 mAb. We report resu...

Descripción completa

Detalles Bibliográficos
Autores principales: Frentzas, Sophia, Kao, Steven, Gao, Rang, Zheng, Hao, Rizwan, Ahsan, Budha, Nageshwar, de la Hoz Pedroza, Luz, Tan, Wei, Meniawy, Tarek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603446/
https://www.ncbi.nlm.nih.gov/pubmed/37857528
http://dx.doi.org/10.1136/jitc-2022-005829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603446/
https://www.ncbi.nlm.nih.gov/pubmed/37857528
http://dx.doi.org/10.1136/jitc-2022-005829

Ejemplares similares